Maxcyte vs its peers
The 5 largest Services-Commercial Physical & Biological Research companies by market value, prices of Nov 20, 2026
Maxcyte is the 5th largest of the 5 biggest Services-Commercial Physical & Biological Research companies on OQRO by market value, at $141M. Its revenue of $33M in fiscal 2025 ranks 3rd of 5. It runs at an operating loss of 157% of revenue, against a group median margin of −157%. Revenue fell 15% on the year before, against a median of −14.5%.
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IconICLR · FY2025 | $14.3B | $8.25B | +0.8% | +24.2% | 26.4% | 5.4% | 2.8% | 10.4% | — | 62.3x | 1.7x | 6.0% | +18.1% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- NRC16%
- ICLR5%
- MXCT−157%
- OABI−369%
- ABSI−4297%
Revenue growth, latest year
- ICLR+0.8%
- NRC−4.0%
- MXCT−14.5%
Compare Maxcyte head to head
Where Maxcyte’s revenue comes from and where it goes: Maxcyte revenue breakdown. Twenty years of results: Maxcyte financial history.
Common questions
Who are Maxcyte's competitors?
The largest companies in its industry (Services-Commercial Physical & Biological Research) by market value: Icon (ICLR), Absci (ABSI), Omniab (OABI) and Nrc Health (NRC). They share Maxcyte's industry listing; not every one competes with it on every product.
Is Maxcyte bigger than Icon?
No, by market value: Maxcyte is worth $141M and Icon $14.3B. By revenue, Maxcyte brought in $33M in fiscal 2025 and Icon $8.25B in fiscal 2025.
How does Maxcyte's valuation compare with its peers?
Maxcyte trades at 4.3x its annual revenue. The median of the other 4 companies is 20.2x revenue and 62.3x earnings. A higher ratio means investors pay more for each dollar the company makes today, usually because they expect it to grow faster.
Where these figures come from
The group is the companies OQRO lists in the same industry as Maxcyte (Services-Commercial Physical & Biological Research), the largest 4 by market value, plus Maxcyte. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.


